UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response	. 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	S)													
1. Name and Address of Reporting Person* Whiteley Andrew P					2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 01/17/2014						X Officer (give title below) Other (specify below) COO, Enzo Life Sciences, Inc.				
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acou										
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				n Date, if	Coc (Ins	le (A	Securities Acqui) or Disposed of str. 3, 4 and 5)	(D) Owne Transa	d 5. Amount of Section Owned Following Transaction(s)			6. Ownership Form:	7. Nature of Indirect Beneficial		
				(Mor	ntn/L	Day/Year)		Code V A	nount (A) or (D)	Price (Instr.	3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
									rm are not red tly valid OMB			ness the r	orm display	S	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	puts,	5. Number of Deriva Securitie Acquired or Dispos of (D)	er ative s l (A) sed	a curren	ed of, or Benefi vertible securitiable and	control nur cially Owne	Amount		9. Number of Derivative Securities Beneficially Owned Following	of 10. Owners Form of Derivat Security Direct (Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	puts,	5. Number of Deriva Securitie Acquired or Dispos	er ative s l (A) sed	a currencequired, Disposits, options, cores 6. Date Exercise Expiration Dat	ed of, or Benefi vertible securitiable and	cially Owned (es) 7. Title and of Underly Securities	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	of 10. Owners Form of Derivat Security Direct (or Indir	hip of Indirect Beneficial Ownersh (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Whiteley Andrew P C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022			COO, Enzo Life Sciences, Inc.			

Signatures

/s/ Andrew P. Whiteley	01/22/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 12,273 options. The options have a five year term which should vest in three equal installments, commencing on January 17, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.